Chromosomal Microarray, Prenatal, ClariSure® Oligo‑SNP
Also known as: Microarray, Genomic Alterations, Comparative Genomic Hybridization, Genomic Alterations, Prenatal Microarray
Use
Chromosomal microarray (CMA) detects aneuploidies, deletions and duplications below the resolution of routine chromosome analysis (karyotyping), and long continuous regions of homozygosity. This assay may be useful for investigation of fetuses with abnormal ultrasound findings, abnormal prenatal screening, definition of unbalanced cytogenetic abnormalities, and follow‑up to a documented chromosome or microarray abnormality in a sibling or a parent. It may also be used as follow up for a family history of developmental delay, intellectual disability, and/or congenital malformations. ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq261?utm_source=openai))
Special Instructions
Not provided.
Limitations
This assay does not detect balanced rearrangements (such as Robertsonian translocations, reciprocal translocations, inversions), low‑level mosaicism below approximately 14% (at 95% confidence), fragile X syndrome, single‑gene disorders (e.g., Marfan syndrome, cystic fibrosis, neurofibromatosis), or very small deletions/duplications below the assay resolution. ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq261?utm_source=openai))
Methodology
Other
Biomarkers
Result Turnaround Time
10-14 days
Related Documents
For more information, please review the documents below
Specimen
Amniotic Fluid
Volume
Not provided
Minimum Volume
Not provided
Container
sterile container
Collection Instructions
Amniotic fluid: 20 mL amniotic fluid in a sterile container. Do not freeze. Amniotic fluid tubes available upon request.